The authors discuss the experience of another group with rapamycin as the principal immunosuppressive drug in HIV positive recipients of liver transplantation. We would suggest that control of HIV-RNA viremia in liver transplanted patients is still a matter of the choice of the best ART independently from the type of the antirejection treatment.
Baccarani U, Adani GL, Tavio M, Grossi P, Viale P. (2010). mTOR Immunosuppression in HIV-Positive Liver Transplant Recipients. TRANSPLANTATION, 90 (9), 1039-1040 [10.1097/TP.0b013e3181f44c1e].
mTOR Immunosuppression in HIV-Positive Liver Transplant Recipients
VIALE, PIERLUIGI
2010
Abstract
The authors discuss the experience of another group with rapamycin as the principal immunosuppressive drug in HIV positive recipients of liver transplantation. We would suggest that control of HIV-RNA viremia in liver transplanted patients is still a matter of the choice of the best ART independently from the type of the antirejection treatment.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
